Drugs / UCAR T-cell
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06939166 | Jun 2025 → Apr 2026 overdue | autoimmune encephalitis, chronic inflammatory demyelinating polyradiculoneuropathy, multiple sclerosis, myasthenia gravis +1 | Tianjin Huanhu Hospital | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07305116 | Dec 2025 → Dec 2028 expected | IgA glomerulonephritis, anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic multidrug-resistant nephrotic syndrome, systemic lupus erythematosus +1 | The Children's Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT06941129 | Feb 2025 → Feb 2028 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune thrombocytopenia, idiopathic inflammatory myopathy, systemic lupus erythematosus +1 | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCAR T-cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06939166 ↗ |
| Modality | Cell therapy | “Universal allogeneic anti-CD19/BCMA CAR T-cells” NCT06939166 ↗ |
| Route | Intravenous | “administered intravenously” NCT06939166 ↗ |
| Target | CD19 | “Universal allogeneic anti-CD19/BCMA CAR T-cells” NCT06939166 ↗ |